Abstract 1689: The combination treatments using siRNA and CDDP are effective therapeutic options for cancers

Abstract

Abstract Background: RNA interference technology has been developed as potential therapeutic options for several diseases, including cancer. Short interfering RNA (siRNA) is the best candidate for cancer therapy because of its specificity and efficiency in gene-specific silencing. We reported that the efficiency of siRNA as novel therapeutic agents for several cancers, such as cholangiocarcinoma, breast cancer and colorectal cancer. Methods: We examined the effect of a combination treatment using Nek2 (NIMA related kinase 2) siRNA with anti cancer agent, CDDP (Cisplatin) on xenograft colorectal cancer mouse model. We next examined the effect of a combination treatment using Tlk1 (Tousled like kinase 1) siRNA with CDDP on MTT assay and TUNEL assay on cholangiocarcinoma cell lines. Results and Discussion: The combination treatment using Nek2 siRNA and CDDP suppressed the tumor growth in colorectal cancer model, more efficiently than negative control siRNA and CDDP. It was more effective than the treatment with Nek2 siRNA alone. The combined administration of Tlk1 siRNA and CDDP strongly induced apoptosis in comparison with negative control siRNA and CDDP on cholangiocarcinoma cell lines. Tlk1 siRNA enhanced DNA damage induced by CDDP treatment. The combination of siRNA and CDDP was effective therapeutic options in colorectal cancer and cholangiocarcinoma. Conclusions: Our data provides a strong rationale for the further investigation concerning the combination of both siRNA and anti cancer drug as a new cancer strategy, holding the potential to provide regression of multiple human malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1689. doi:10.1158/1538-7445.AM2011-1689